Clinical Trials on Sorafenib

Total 13 results

Southwest Hospital, China
Xijing Hospital; Xiangya Hospital of Central South University; Henan Cancer Hospital and other collaborators

Unknown

Combined Treatment of RFA and Sorafenib on Recurrent HCC (REPEAT)

HCC | Radiofrequency Ablation | Sorafenib

China
Shanghai Zhongshan Hospital

Recruiting

A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC

Donafenib

China
University Hospital Tuebingen
German Federal Ministry of Education and Research

Terminated

Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC (e:Med-HCC-2)

Hepatocellular Carcinoma | Sorafenib

Germany
Sun Yat-sen University

Completed

Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC) (2011PTAHCC)

Hepatocellular Carcinoma | Hepatectomy | Sorafenib

China
Shandong Cancer Hospital and Institute

Unknown

TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular | PHENYTOIN/SORAFENIB [VA Drug Interaction]

China
Sun Yat-sen University

Completed

TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma (TREAT)

Hepatocellular Carcinoma | Sorafenib | Transarterial Chemoembolization

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma (SIRAHCC)

Hepatocellular Carcinoma, Radiotherapy, Sorafenib

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

Advanced Hepatocellular Carcinoma | Radiotherapy | Sorafenib | Toripalimab

China
Shandong Cancer Hospital and Institute

Unknown

Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma

Liver Diseases | Neoplasms by Histologic Type | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Digestive System Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms | HBV | PHENYTOIN/SORAFENIB [VA Drug Interaction] | DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]

China
Shanghai Zhongshan Hospital

Recruiting

A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice

Hepatocellular Carcinoma | Donafenib

China
Sichuan Cancer Hospital and Research Institute

Recruiting

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Liver Diseases | Digestive System Neoplasms | Liver Neoplasms | Hepatocellular Carcinoma | Antineoplastic Agents | Molecular Mechanisms of Pharmacological Action | Protein Kinase Inhibitors | Sorafenib

China
Shanghai Zhongshan Hospital

Recruiting

A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC

Hepatocellular Carcinoma | Donafenib

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Huashan Hospital; The Second Affiliated Hospital of Harbin Medical University; Meng Chao Hepatobiliary Hospital of Fujian Medical University

Not yet recruiting

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Carcinoma | Digestive System Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms | Antineoplastic Agents | Oxaliplatin | Donafenib | Fluorouracil | Antimetabolites

China

Clinical Trials on Sorafenib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations